AAAAAA

   
Results: 1-11 |
Results: 11
A case of familial hypercholesterolemia caused by a novel mutation D461Y in the low density lipoprotein receptor gene
Authors: Krapivner, SR Malyshev, PP Poltaraus, AB Kukharchuk, VV Bochkov, VN
Citation: Sr. Krapivner et al., A case of familial hypercholesterolemia caused by a novel mutation D461Y in the low density lipoprotein receptor gene, KARDIOLOGIY, 41(1), 2001, pp. 92-94
Plasma acid-stable trypsin inhibitor in patients with chronic renal insufficiency.
Authors: Belova, LL Ogloblina, OG Kukharchuk, VV Palvanova, KD Sepaeva, IG Malginov, SV Kutsenko, AI Arabidze, GG
Citation: Ll. Belova et al., Plasma acid-stable trypsin inhibitor in patients with chronic renal insufficiency., GEMATOL TR, 45(1), 2000, pp. 19-22
Application of DNA analysis for differential diagnosis of familial hypercholesterolemia and familial defective apolipoprotein B-100
Authors: Krapivner, SR Malyshev, PP Rozhkova, TA Poltaraus, AB Kukharchuk, VV Bochkov, VN
Citation: Sr. Krapivner et al., Application of DNA analysis for differential diagnosis of familial hypercholesterolemia and familial defective apolipoprotein B-100, TERAPEVT AR, 72(4), 2000, pp. 9-12
Activity of chymotrypsin-like proteinases in patients with ischemic heart disease, arterial hypertension and nonspecific aortic arteritis
Authors: Arabidze, GG Belova, LA Chikhladze, NM Shapkina, LS Ogloblina, OG Kukharchuk, VV
Citation: Gg. Arabidze et al., Activity of chymotrypsin-like proteinases in patients with ischemic heart disease, arterial hypertension and nonspecific aortic arteritis, TERAPEVT AR, 72(11), 2000, pp. 36-39
Diagnosis of familial hypercholesterolemia at pre-clinical stage by analysis of DNA
Authors: Krapivner, SR Malyshev, PP Poltaraus, AB Meshkov, AN Kukharchuk, VV Bochkov, VN
Citation: Sr. Krapivner et al., Diagnosis of familial hypercholesterolemia at pre-clinical stage by analysis of DNA, KARDIOLOGIY, 40(2), 2000, pp. 4-7
Cerivastatin - A new synthetic 3-hydroxy-3-methylglutaryl (HMG) inhibitor:Effect of 0.2 mg dose in patients with primary hyperlipidemias
Authors: Solovyeva, EY Rozhkova, TA Tvorogova, MG Kukharchuk, VV
Citation: Ey. Solovyeva et al., Cerivastatin - A new synthetic 3-hydroxy-3-methylglutaryl (HMG) inhibitor:Effect of 0.2 mg dose in patients with primary hyperlipidemias, TERAPEVT AR, 71(8), 1999, pp. 30-34
Levels of biologically active substances in the blood of patients responsive and unresponsive to antihypertensive therapy
Authors: Tabakyan, EA Dmitriev, VV Masenko, VP Kukharchuk, VV
Citation: Ea. Tabakyan et al., Levels of biologically active substances in the blood of patients responsive and unresponsive to antihypertensive therapy, TERAPEVT AR, 71(3), 1999, pp. 62-67
Plasma sialyltransferase activity in healthy subjects and atherosclerotic patients
Authors: Gracheva, EV Golovanova, NK Ezhov, MV Malyshev, PP Kukharchuk, VV Prokazova, NV
Citation: Ev. Gracheva et al., Plasma sialyltransferase activity in healthy subjects and atherosclerotic patients, BIOCHEM-MOS, 64(11), 1999, pp. 1315-1319
Lipanor treatment of atherogenic hyperlipoproteinemia
Authors: Susekov, AV Tvorogova, MG Arabidze, GG Kukharchuk, VV
Citation: Av. Susekov et al., Lipanor treatment of atherogenic hyperlipoproteinemia, TERAPEVT AR, 70(9), 1998, pp. 57-61
Factors of renal disease progress and probability of regulating these factors in principle
Authors: Tvorogova, MG Susekov, AV Semenova, OA Kukharchuk, VV Titov, VN
Citation: Mg. Tvorogova et al., Factors of renal disease progress and probability of regulating these factors in principle, TERAPEVT AR, 70(12), 1998, pp. 5-8
Variability of the hypolipidemic action of simvastatin and fluvastatin in patients with primary hyperlipoproteinemia
Authors: Tvorogova, MG Susekov, AV Semenova, OA Kukharchuk, VV Titov, VN
Citation: Mg. Tvorogova et al., Variability of the hypolipidemic action of simvastatin and fluvastatin in patients with primary hyperlipoproteinemia, TERAPEVT AR, 70(12), 1998, pp. 8-13
Risultati: 1-11 |